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Purpose: Histopathologic studies have reported retinal nerve fiber layer (RNFL) thinning 
in various neurodegenerative diseases. Attempts to quantify this loss in vivo have relied on 
  time-domain optical coherence tomography (TDOCT), which has low resolution and requires 
substantial interpolation of data for volume measurements. We hypothesized that the significantly 
higher resolution of spectral-domain optical coherence tomography (SDOCT) would better 
detect RNFL changes in patients with multiple sclerosis, and that RNFL thickness differences 
between eyes with and without optic neuritis might be identified more accurately.
Methods: In this retrospective case series, patients with multiple sclerosis were recruited 
from the Judith Jaffe Multiple Sclerosis Center at Weill Cornell Medical College in New York. 
Patients with a recent clinical diagnosis of optic neuritis (less than three months) were excluded. 
Eyes with a history of glaucoma, optic neuropathy (other than multiple sclerosis-related optic 
neuritis), age-related macular degeneration, or other relevant retinal and/or optic nerve disease 
were excluded. Both eyes of each patient were imaged with the Heidelberg Spectralis® HRA + 
OCT. RNFL and macular thickness were measured for each eye using the Heidelberg OCT 
software. These measurements were compared with validated published normal values, and 
were modeled as linear functions of duration of disease. The odds of an optic neuritis diagnosis 
as a function of RNFL and macular thickness were calculated.
Results: Ninety-four eyes were prospectively evaluated using OCT. Ages of patients ranged from 
26 to 69 years, with an average age of 39 years. Peripapillary RNFL thinning was demonstrated in 
multiple sclerosis patients; mean RNFL thickness was 88.5 µm for individuals with multiple sclerosis 
compared with a reported normal value of 97 µm (P , 0.001). Eyes with a history of optic neuritis 
had more thinning compared with those without optic neuritis (83.0 µm versus 90.5 µm, respectively, 
P = 0.02). No significant differences were observed in macular thickness measurements between eyes 
with and without optic neuritis, nor were macular thickness measurements significantly different from 
normal values. As a function of multiple sclerosis duration and controlling for age, RNFL thickness 
was decreased in patients with a duration of multiple sclerosis greater than five years compared with 
those with a duration less than or equal to one year (P = 0.008).
Conclusions: Patients with a history of multiple sclerosis had RNFL thinning that was detect-
able on SDOCT. Decreasing RNFL thickness in eyes with optic neuritis was found, and the odds 
of having optic neuritis were increased significantly with decreasing RNFL thickness. Average 
RNFL thinning with increasing duration of disease was an excellent predictor of a reported 
history of optic neuritis. SDOCT retinal imaging may represent a high-resolution, objective, 
noninvasive, and easily quantifiable in vivo biomarker of the presence of optic neuritis and 
severity of multiple sclerosis.
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Neurodegenerative diseases such as multiple sclerosis, 
Alzheimer disease, and Parkinson’s disease, are characterized 
by axonal lesions throughout the central nervous system, 
including the eye.1 Specifically with multiple sclerosis, 
  histopathologic studies have reported retinal nerve fiber layer 
(RNFL) thinning, and these changes have been correlated 
with disease activity and white matter lesion volume on neu-
roradiologic studies, such as magnetic resonance imaging.2–5 
The ease of in vivo cross-sectional retinal tissue imaging 
with optical coherence tomography (OCT) facilitates the 
use of the retina as a surrogate for multiple sclerosis disease 
activity. Prior attempts to quantify RNFL loss and to monitor 
multiple sclerosis patients have almost exclusively been with 
time-domain OCT (TDOCT).1,6–21
In addition to having a significantly lower axial resolution, 
TDOCT has limited image acquisition, retinal segmentation, 
and precise long-term monitoring capabilities. On the other 
hand, spectral-domain OCT (SDOCT), the newest iteration 
of OCT technology, is characterized by markedly increased 
image acquisition speed and improved axial resolution, 
among other features, and has been increasingly utilized for 
evaluation of a variety of ocular diseases, such as glaucoma, 
age-related macular degeneration, macular hole, epiretinal 
membrane, and diabetic macular edema. RNFL thickness 
measurement with this technology has been reported to be 
more reliable and reproducible compared with TDOCT.22–24 
Exploitation of SDOCT’s features and advantages compared 
with TDOCT could greatly improve and expand the means 
of detection and monitoring of multiple sclerosis disease 
activity.
We hypothesize that SDOCT imaging of the retina 
in patients with multiple sclerosis may provide a high-
  resolution, objective, noninvasive, and easily quantifiable 
in vivo biomarker of severity of disease and presence of 
optic neuritis. To the best of our knowledge, this report 
represents one of the first such assessments of the retina in 
multiple sclerosis patients specifically with high-resolution 
SDOCT.25,26
Methods
This was a retrospective case series approved by the Weill 
Cornell Medical College Institutional Review Board. 
  Subjects were recruited from the Judith Jaffe Multiple 
  Sclerosis Center, Weill Cornell Medical College,   Department 
of Neurology, in New York. Optic nerve and macular imag-
ing was performed in the Department of Ophthalmology at 
Weill Cornell Medical College. Subjects with a   diagnosis 
of multiple sclerosis, with or without a history of optic 
neuritis, were included. Eyes with a history of glaucoma, 
optic neuropathy (other than multiple sclerosis-related 
optic neuritis), age-related macular degeneration, or other 
relevant retinal or optic nerve diseases were excluded. 
Patients with a recent history of optic neuritis (less than three 
months’ duration) were also excluded. Both eyes of each 
patient were imaged with the high-resolution Heidelberg 
  Spectralis® HRA + OCT (Heidelberg   Engineering, Germany) 
by a trained operator (GJP, GDA, AAK, or SK). Scanning 
protocols included both a circular 3.4 mm scan centered on 
the optic nerve head and a volumetric scan of the macula 
centered on the fovea (73 horizontal B-scans covering a 
  superior-to-inferior distance of 4.6 mm). In a setting separate 
from image acquisition, a masked observer excluded poor 
quality images from the final analysis (AAK). RNFL and 
macular thickness were measured for each eye using the 
Heidelberg software. To ensure improved accuracy in both 
RNFL and macular thickness measurements, each scan was 
individually reviewed, and appropriate adjustments of the 
segmentation lines were made in a masked fashion. RNFL 
measurements were reported by sector, ie, temporal, super-
otemporal,   superonasal, nasal,   inferonasal, inferotemporal, 
and average (see Figure 1). These RNFL measurements were 
compared with the   Heidelberg normative database. Macular 
thickness was reported in a modified ETDRS (Early Treat-
ment of Diabetic Retinopathy Study) macular map with 
the central subfield 1.00 mm in diameter, and the inner and 
outer subfields having diameters of 2.22 mm and 3.45 mm, 
respectively.
Summary statistics, including age, gender, and duration 
of disease were compared between the subjects with optic 
neuritis (in either or both eyes) and those without optic 
neuritis (in either eye) using the Mann–Whitney U test for 
differences in age and duration of disease, and Fisher’s exact 
test for differences in gender distribution between groups.
The normality of the data distributions for RNFL 
and macular thickness measurements were checked with 
the Shapiro–Wilk test. Sample t-tests were conducted to 
compare average RNFL and macular thickness measure-
ments of multiple sclerosis patients and published normal 
measurements. RNFL thicknesses were compared with the 
50th percentile values provided in the validated Heidelberg 
software.   Macular thickness measurements were compared 
with published normative values.27
To determine the relative chance of a diagnosis of optic 
neuritis given an eye’s decreasing RNFL or macular thick-
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using generalized estimating equations while adjusting for 
age and correlation between the right and left eyes of the 
same patient. Generalized estimating equations were also 
used to model RNFL and macular thickness as a function 
of duration of disease, while adjusting for age and intereye 
correlation. Semirobust variance estimation (Huber–White 
sandwich estimator) was used to estimate the standard error 
of parameters,28 and model selection was guided by the quasi-
likelihood under the independence model criterion method.29 
Analyses were performed using Stata/IC 11.0 (StataCorp, 
College Station, TX). All statistical tests were two-sided with 
a level of significance of 0.05.
Results
Peripapillary and macular OCT imaging was performed on 
94 eyes of patients with multiple sclerosis. No images were 
excluded from the final analysis due to poor image quality. 
Patient age ranged from 26 to 69 years (median 39 years). 
The median ages of patients with and without optic neuritis 
were 40 and 33 years, respectively. The percentage of sub-
jects who were female was 68.1%, and for females with and 
without optic neuritis the percentages were 84.0% and 62.3%, 
respectively. Median disease duration for all subjects with 
multiple sclerosis was 30.9 months, and for subjects with 
and without optic neuritis, median disease duration was 54.0 
and 30.3 months, respectively. No   significant differences 
with regard to age, gender, or disease duration were found 
between eyes with and without optic neuritis.
Peripapillary RNFL thinning was demonstrated (Table 1); 
mean thickness was 88.5 µm (P , 0.001) for individuals 
with multiple sclerosis when compared with eyes of patients 
  without multiple sclerosis (normals, 97 µm). Eyes with a 
history of optic neuritis had thinner RNFL measurements 
than those without a history of optic neuritis (83.0 µm versus 
90.5 µm, respectively, P = 0.02).
Five subjects declined to have macular scanning per-
formed, therefore macular thickness was measured in only 
84 of 94 eyes (Table 1). The mean central subfield thick-
ness for all eyes was 270.9 µm, compared with 270.2 µm 
for   Heidelberg device-specific published normative data 
(P . 0.05).27 Macular thinning in the inner nasal, outer 
nasal, and outer inferior sectors of all multiple sclerosis 
subjects when compared with controls was noted (331.2 µm, 
P = 0.03; 331.9 µm, P , 0.001; and 320.2 µm, P = 0.004, 
respectively).
Decreasing RNFL thickness measurements were associ-
ated with an increased risk of having a diagnosis of optic 
neuritis in that eye (Table 2). For example, a 5 µm decrease 
in average RNFL thickness was likely to increase the odds of 
having a diagnosis of optic neuritis (OR 1.33, 95% confidence 
interval [CI] 1.08–1.67, P = 0.009).
Increased average RNFL thinning with increased 
duration of disease was demonstrated (Table 3). The 
average RNFL thickness for subjects with disease dura-
tion greater than 60 months was less than that measured 
in subjects with a less than 13-month disease duration 
(P = 0.008). However, there was no significant difference 
in average RNFL thickness for those with 13–60 months’ 
disease duration compared with those with less than 
13 months’ disease duration (P = 0.25). Macular thickness 
Figure 1 Comparative time-domain and spectral-domain OCT scans of peripapillary rnFL and macula in subjects with multiple sclerosis. in all four panels, OCT B-scans 
are accompanied by the corresponding fundus images indicating B-scan locations. Upper left: heidelberg spectralis® hrA + OCT Circular B-scan. red lines represent inner 
and outer boundaries of the rnFL. Upper right: heidelberg spectralis® hrA + OCT macular thickness scan composed of 73 horizontal B-scans within the green box area. 
Top red line represents the vitreoretinal interface (ie, inner boundary of macular thickness measurement). Bottom red line represents retinal pigment epithelium-choroid 
interface (ie, outer boundary of macular thickness measurement). Lower left: stratus OCT Circular B-scan. White lines represent inner and outer boundaries of rnFL. 
Lower right: stratus OCT macular thickness scan composed of six radial B-scans. Top white line represents the vitreoretinal interface, and bottom white line represents the 
inner segment-outer segment interface. 





  measurements were not observed to vary as a function of 
disease duration.
Discussion
To our knowledge, this study is one of the first to utilize 
high-resolution SDOCT to study retinal changes in patients 
with multiple sclerosis.25,26 Utilizing the Heidelberg 
  Spectralis® HRA + OCT, we were able to demonstrate 
significant RNFL thinning in multiple sclerosis patients 
compared with   controls. As well as in eyes with optic neu-
ritis compared with those without optic neuritis. In general, 
prior studies with low-resolution TDOCT are consistent 
with our findings using SDOCT.
Kerrison et al, using histopathologic analysis, demon-
strated a loss of RNFL thickness in the temporal quadrant in 
multiple sclerosis-affected eyes.30 Parisi et al, using an early 
iteration of TDOCT technology, demonstrated reduced tem-
poral and overall RNFL thickness in eyes with and without 
optic neuritis when compared with controls.18 Fisher et al, 
using the Stratus TDOCT, similarly detected a reduction in 
RNFL thickness in subjects with multiple sclerosis, in addi-
tion to demonstrating an RNFL thickness difference between 
eyes with and without optic neuritis.16 Costello et al, using the 
Stratus TDOCT device, demonstrated a   difference in RNFL 
thickness between eyes with and without optic neuritis.15 
Table 1 Mean rnFL thickness measurements (top, µm) and mean macular thickness measurements (bottom, µm) with the heidelberg 
spectralis® hrA + OCT in patients with Ms. Mean rnFL thickness for all eyes compared with normative data. 
RNFL Normal* All MS (94) P Non-ON (69) ON (25) P
Temporal  74 62.6 ± 15.2 ,0.001 65.2 ± 4.4 55.5 ± 15.5 0.006
superior-temporal  133 119.8 ± 23.7 ,0.001 123.0 ± 23.3 110.9 ± 23.1 0.03
superior-nasal  105 96.1 ± 26.1 0.001 96.8 ± 26.1 94.5 ± 26.4 0.71
nasal  72 65.7 ± 17.5 ,0.001 66.8 ± 18.1 62.8 ± 15.8 0.33
inferior-nasal  107 103.8 ± 26.2 0.23 105.0 ± 25.0 100.4 ± 29.6 0.45
inferior-temporal  140 130.4 ± 21.3 ,0.001 134.2 ± 21.0 119.9 ± 18.9 0.004
superior  – 107.9 ± 21.4 – 109.8 ± 21.7 102.7 ± 20.1 0.16
inferior  – 117.0 ± 18.8 – 119.3 ± 17.9 110.5 ± 20.1 0.04
Average 97 88.5 ± 13.8 ,0.001 90.5 ± 13.2 83.0 ± 14.0 0.02
Macula Normal† All MS (84) P Non-ON (59) ON (25) P
inner temporal 322.6 323.1 ± 14.5 0.76 325.3 ± 14.5 317.8 ± 13.1 0.02
inner superior 336.0 332.7 ± 17.0 0.08 335.2 ± 17.5 327.0 ± 14.6 0.05
inner nasal 335.0 331.2 ± 16.3 0.03 332.9 ± 17.1 327.2 ± 13.9 0.14
inner inferior 334.9 334.0 ± 16.1 0.62 336.3 ± 16.3 328.6 ± 14.4 0.04
Outer temporal 320.1 317.6 ± 15.2 0.14 319.0 ± 14.2 314.3 ± 17.0 0.19
Outer superior 329.6 327.8 ± 18.9 0.38 329.6 ± 18.9 323.6 ± 18.4 0.19
Outer nasal 339.5 331.9 ± 18.0 ,0.001 334.3 ± 17.8 326.3 ± 17.6 0.06
Outer inferior 325.4 320.2 ± 16.2 0.004 322.4 ± 15.5 314.9 ± 16.9 0.05
Central subfield 270.2 270.9 ± 17.3 0.72 273.0 ± 18.0 265.9 ± 14.4 0.08
Note: *Mean macular thickness for all eyes compared with published controls. Thickness measurements from eyes without On are compared with those of eyes with On. 
Eyes affected by MS show statistically significant RNFL thinning compared with normals. MS subjects with a history of OP have an even greater thinning than those without 
a  history of On. Ms subjects have inner nasal, outer nasal, and outer inferior macular thinning compared with published normals.27 †
Abbreviations: MS, multiple sclerosis; OCT, optical coherence tomography; ON, optic neuritis; RNFL, retinal nerve fiber layer.
Finally, Trip et al showed a difference in RNFL thickness 
between optic neuritis-affected eyes and controls as well 
as between optic neuritis-affected eyes and optic neuritis-
unaffected eyes, however, no difference was detected 
between optic neuritis-unaffected eyes and controls.20 Other 
investigators utilizing SDOCT demonstrated significant 
RNFL thinning in eyes of patients with multiple sclerosis 
compared with healthy eyes, but they found differences in 
all four quadrants in addition to average thickness. How-
ever, they did not evaluate differences between eyes with 
and without optic neuritis, nor did they evaluate macular 
  thickness measurements in these subjects.25
In the current study, patients with multiple sclerosis had 
significantly thinner inner nasal and outer nasal maculas 
than normal, and those eyes affected by optic neuritis had 
significant macular thinning compared with eyes unaf-
fected by optic neuritis only in the outer temporal segment. 
Regarding the cohort with multiple sclerosis as a whole, 
nasal macular thinning is consistent with our peripapillary 
RNFL findings. Because the papillomacular bundle is 
located in the nasal macula, peripapillary RNFL thinning 
may result in a thinner macula secondary to loss of the 
RNFL in that region. Similar to our findings with SDOCT, 
Gugleta et al reported macular thinning in subjects with 
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affected or not affected by optic neuritis.31 Other investiga-
tors have demonstrated decreases in total macular volume in 
subjects with multiple sclerosis compared with controls,6,13,32 
while decreases in macular volume in optic neuritis-affected 
eyes compared with optic neuritis-unaffected eyes have been 
reported as well.13,20,32,33
Although these earlier findings of macular volume abnor-
malities may be consistent with the concept of thinning sec-
ondary to axonal degeneration from multiple sclerosis and do 
not contradict our findings, the early reports, utilizing TDOCT 
exclusively, should be interpreted with caution. Calculation of 
total macular volume on a TDOCT device such as the Stratus® 
OCT requires a significant amount of interpolation because 
only six radial scans centered on the fovea are acquired. This 
is in contrast with potentially over 100 horizontal scans volu-
metrically acquired across the macula with SDOCT.
Multiple sclerosis is a progressive disease in which 
subclinical RNFL thinning may occur, even in patients who 
have not been clinically diagnosed with optic neuritis.15,16,18 
In our study, we demonstrated progressive peripapillary 
RNFL thinning with increased duration of disease of more 
than five years, even in multiple sclerosis patients who do 
not manifest overt optic neuritis. Previously published reports 
using TDOCT have not consistently demonstrated such a 
relationship.6
In the current study, decreasing RNFL thickness was 
an excellent predictor of a previous diagnosis of optic 
neuritis in affected eyes (Table 2). This is evidenced by a 
significantly elevated risk of optic neuritis with peripapil-
lary RNFL thinning. Given the retrospective nature of our 
study, larger prospective studies with SDOCT should be 
undertaken to define better an ideal RNFL thickness cutoff 
that is most likely to predict presence or absence of optic 
neuritis.
To our knowledge, our report represents one of the first 
such investigations of multiple sclerosis patients using high-
resolution SDOCT technology, given that most previously 
published reports utilized the older, much lower-resolution 
TDOCT. The difference between TDOCT and SDOCT is not 
trivial, ie, 400 A-scans/sec versus 40,000 A-scans/sec, 10 µm 
versus 5 µm axial resolution, and six radial scans versus 100 
to 145 horizontal scans for calculating macular volume for 
TDOCT versus SDOCT, respectively.
While previous investigators have demonstrated retinal 
changes using TDOCT in multiple sclerosis patients, the potential 
for improved precision, accuracy, point-by-point follow-up 
visit registration, and earlier detection of disease with SDOCT 
cannot be ignored. In addition to the technologic improve-
ments listed above, SDOCT has other advantages, ie, true 
volumetric calculations (much less interpolation), image regis-
tration enabling accurate long-term monitoring, and improved 
image segmentation, facilitating analysis of specific retinal 
layers. Patients with multiple sclerosis, particularly those with 
subclinical eye disease (unaffected by optic neuritis), may have 
retinal microstructural changes that are imperceptible to the 
lower-resolution TDOCT.
A major challenge in utilizing SDOCT imaging is the 
abundance of machines on the market, each with distinct seg-
mentation algorithms and normative databases. These issues 
must be taken into account when attempting to compare 
results obtained from different machines. While relatively 
few results have been reported with SDOCT technology in 
patients with multiple sclerosis, one group of researchers has 
reported high reliability of SDOCT for RNFL measurement 
in this setting.26 Bock et al demonstrated high correlation 
of RNFL measurements between a TDOCT and a SDOCT 
machine, but they also reported significant differences in 
corresponding measurements.25 Therefore, although some 
of the findings in our study parallel those of TDOCT-derived 
studies, it is best to make conclusions from data obtained 
from each machine separately because the absolute values 
of measurements cannot necessarily be compared between 
TDOCT and SDOCT, or even between two different SDOCT 
Table  2  Or  of  an  optic  neuritis  diagnosis  as  a  function  of 
rnFL and macular thickness measurements with the heidelberg 
spectralis® hrA + OCT in patients with multiple sclerosis and an 
Or of an optic neuritis diagnosis per 5 µm decrease in rnFL or 
macular thickness
Location OR P
rnFL Temporal  1.33 0.008
superior-temporal  1.15 0.04
superior-nasal  1.04 0.37
nasal  1.14 0.11
inferior-nasal  1.08 0.25
inferior-temporal  1.18 0.008
superior  1.12 0.08
inferior  1.16 0.04
Average 1.33 0.009
Macular Thickness inner temporal 1.19 0.06
inner superior 1.15 0.08
inner nasal 1.10 0.22
inner inferior 1.16 0.10
Outer temporal 1.08 0.50
Outer superior 1.09 0.32
Outer nasal 1.14 0.12
Outer inferior 1.15 0.19
Central subfield 1.11 0.18
Abbreviations: OCT, optical coherence tomography; RNFL, retinal nerve fiber 





machines.22,25,34 As an example, the Heidelberg software mea-
sures macular thickness from the internal limiting membrane 
to the bottom of the retinal pigment epithelium, the Topcon 
software measures from the internal limiting membrane to 
the top of the retinal pigment epithelium, and the Stratus 
measures from the internal limiting membrane to the pho-
toreceptor inner segment/outer segment interface. Despite 
these challenges, future investigations utilizing imaging 
biomarkers for the monitoring of multiple sclerosis should 
utilize the more modern SDOCT rather than conventional 
TDOCT.
Future prospective investigations of multiple sclerosis-
related retinal changes should consider these findings when 
following subjects longitudinally. The retinal changes 
reported here need to be validated in multiple sclerosis dis-
ease subsets, and correlated with magnetic resonance imaging 
findings and measures of visual function, including visual 
acuity, contrast sensitivity, visual fields, microperimetry, 
vision-evoked potentials, and electroretinography. Nonethe-
less, as our findings demonstrate, SDOCT retinal imaging 
may represent a high-resolution, objective, noninvasive, and 
easily quantifiable in vivo biomarker of the presence of optic 
neuritis and severity of multiple sclerosis. It may also serve 
as a diagnostic adjunct for monitoring disease activity and 
response to treatment.
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